# Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

Study · id `cardio:ct-nct01147250` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01147250](<https://clinicaltrials.gov/study/NCT01147250>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01147250

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 6068 participants.

## Technical summary

Registry record NCT01147250. Randomized; triple masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2015-02 (actual). Results posted on 2016-10-14.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 6068 participants (enrolled count; ClinicalTrials.gov record NCT01147250, source copy `cardio:ctgov-nct01147250-2016-12-20`, retrieved 2026-10-31)
- Start date: 2010-06 (registry gives no type) (ClinicalTrials.gov record NCT01147250, source copy `cardio:ctgov-nct01147250-2016-12-20`, retrieved 2026-10-31)
- Primary completion: 2015-02 (actual) (ClinicalTrials.gov record NCT01147250, source copy `cardio:ctgov-nct01147250-2016-12-20`, retrieved 2026-10-31)
- Completion: 2015-02 (actual) (ClinicalTrials.gov record NCT01147250, source copy `cardio:ctgov-nct01147250-2016-12-20`, retrieved 2026-10-31)
- Results first posted: 2016-10-14 (ClinicalTrials.gov record NCT01147250, source copy `cardio:ctgov-nct01147250-2016-12-20`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Austria; Belarus; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Denmark; Ecuador; Egypt; Estonia; Finland; France; Georgia; Germany; Guatemala; India; Israel; Italy; Japan; Latvia; Lithuania; Mexico; Netherlands; Norway; Panama; Peru; Philippines; Poland; Portugal; Romania; Russia; Serbia; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan; Tunisia; Türkiye; Ukraine; United Arab Emirates; United Kingdom (ClinicalTrials.gov record NCT01147250, source copy `cardio:ctgov-nct01147250-2016-12-20`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01147250-2016-12-20`, retrieved 2026-10-31)

## The registry's words

- Brief title: Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
- Acronym: ELIXA
- Condition: Acute Coronary Syndrome
- Intervention (Drug): Lixisenatide (AVE0010)
- Intervention (Drug): Placebo
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome (`cardio:pubmed-26630143`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus (`cardio:pubmed-28554908`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration (`cardio:pubmed-30648112`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 60c99e17a3b9d80ab11367e4df2b1d36d2657b5561819f602a268e4ec3c60624
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
